Abstract
Sepsis is one of the leading causes of mortality in non-cardiac intensive care units, and the need for markers of progression and severity are high. Also, treatment of sepsis is highly debated and potential new targets of treatment are of great interest. In the previous issue of Critical Care Kumaraswamy and colleagues have investigated whether plasma apolipoprotein M (apoM) is affected during different grades of sepsis, septic shock and systemic inflammatory response syndrome. Interestingly, plasma apoM was significantly decreased in all groups of patients with a relationship to severity of disease. This identifies apoM as a potential new biomarker in sepsis. It also underscores the possibility that altered high-density lipoprotein in sepsis patients can affect the course of disease. Thus, since apoM is the carrier of Sphingosine-1-P (S1P), a molecule with great influence on vascular barrier function, the study presented raises the interest and relevance for further studies of apoM and S1P in relation to sepsis and inflammation.
Highlights
Sepsis is one of the leading causes of mortality in noncardiac intensive care units, and the need for markers of progression and severity are high
In the previous issue of Critical Care, Kumaraswamy and colleagues [1] show that plasma apolipoprotein M is reduced in patients with sepsis and systemic inflammatory response syndrome (SIRS)
This is the first report of such a dramatic decrease in plasma apolipoprotein M (apoM) in a group of patients without genetic diseases affecting high-density lipoprotein metabolism but solely based on clinical scores for sepsis
Summary
Sepsis is one of the leading causes of mortality in noncardiac intensive care units, and the need for markers of progression and severity are high. In the previous issue of Critical Care, Kumaraswamy and colleagues [1] show that plasma apolipoprotein M (apoM) is reduced in patients with sepsis and systemic inflammatory response syndrome (SIRS). This is the first report of such a dramatic decrease in plasma apoM in a group of patients without genetic diseases affecting high-density lipoprotein metabolism but solely based on clinical scores for sepsis.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
